Bisphenol A induces cell cycle arrest in primary and prostate cancer cells through EGFR/ERK/p53 signaling pathway activation
Metrics: PDF 762 views | HTML 1520 views | ?
Antonio Bilancio1,*, Paola Bontempo1,*, Marzia Di Donato1,*, Mariarosaria Conte2, Pia Giovannelli1, Lucia Altucci1, Antimo Migliaccio1 and Gabriella Castoria1
1Department of Biochemistry, Biophysics and General Pathology, University of Campania “L. Vanvitelli”, Naples, Italy
2IRCCS, SDN, Naples, Italy
*These authors have contributed equally to this work
Antimo Migliaccio, email: firstname.lastname@example.org
Keywords: BPA; prostate cancer; cell cycle; AR; erk
Received: October 30, 2017 Accepted: December 03, 2017 Published: December 18, 2017
Bisphenol A (BPA) belongs to the class of chemicals known as endocrine disruptors and has been also involved in the pathogenesis and progression of endocrine related cancer such as breast and prostate cancers. Here, we have investigated the effect of BPA in human prostate cancer LNCaP cells and in human non-transformed epithelial prostate EPN cells. Our data showed that BPA induces the down regulation of cyclin D1 expression and the upregulation of the cell cycle inhibitors p21 and p27, leading to cell cycle arrest. Interestingly, we found that the BPA anti-proliferative response depends on a strong and rapid activation of epidermal growth factor receptor (EGFR), which stimulates ERK-dependent pathway. This, in turn, induces expression of p53 and its phosphorylation on residue Ser15, which is responsible for cell cycle arrest. EGFR activation occurs upon a cross talk with androgen (AR) and estradiol receptor-β (ERβ) which are known to bind BPA.
Altogether, these findings show a novel signaling pathway in which EGFR activation plays a key role on BPA-induced cell cycle inhibition through a pathway involving AR and ERβ/EGFR complexes, ERK and p53. Our results provide new insights for understanding the molecular mechanisms in human prostate cancer. On the other, they could allow the development of new compounds that may be used to overcome human prostate cancer resistance to endocrine therapy in promising target therapeutic approaches.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.